US › Healthcare

Bicycle Therapeutics Ltd (BCYC)

US · Healthcare · Biotechnology

$3.61+3.74%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$34.1M

Revenue YoY

+190.2%

Net profit

$-10.5M

EPS

$-0.15

EPS estimate

$-0.30

Net margin

-30.8%

EPS came in at -0.15 against a street estimate of -0.30 — a beat of 50.0%.

Key statistics

Market cap

$243.9M

Forward P/E

0.0

P/B

0.51

Book value

$7.22

EPS (TTM)

$-2.03

52-week high

$7.83

52-week low

$3.33

50-day MA

$3.79

200-day MA

$4.52

Beta

1.60

Analyst view

Analysts rate Bicycle Therapeutics Ltd a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $9.17.

Shareholding

Insiders

4.59%

Institutions

71.68%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	15.55%
FCPM III SERVICES BV	4.96%
Armistice Capital, LLC	4.85%
Long Focus Capital Management, LLC	4.73%
Acadian Asset Management LLC	2.81%
Renaissance Technologies Corp	2.19%
GSK PLC	2.19%
T. Rowe Price Associates, Inc.	1.29%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bicycle Therapeutics Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.